Sonoma Pharmaceuticals (SNOA) Set to Release Quarterly Earnings on Monday

Sonoma Pharmaceuticals (NASDAQ:SNOA) is projected to announce its resultson Monday, November 16th. Analysts expect the company to post earnings of ($0.10) per share and revenue of $5.29 million for the quarter.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.32. The firm had revenue of $6.41 million for the quarter, compared to analyst estimates of $4.99 million. Sonoma Pharmaceuticals had a negative net margin of 10.33% and a negative return on equity of 21.41%.

Sonoma Pharmaceuticals Stock Performance

NASDAQ SNOA opened at $1.11 on Monday. Sonoma Pharmaceuticals has a 1 year low of $0.85 and a 1 year high of $3.95. The business’s fifty day moving average is $1.22 and its two-hundred day moving average is $1.67. The stock has a market capitalization of $5.32 million, a P/E ratio of -0.91 and a beta of 1.31.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut Sonoma Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 21st. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing non-antibiotic and non-steroidal products for human and animal health. Its products are designed for applications including dermatology, wound care, eye care and veterinary treatment.

The company’s product portfolio is based primarily on Microcyn technology, a stabilized hypochlorous acid solution intended to cleanse, debride and manage wounds and various skin conditions.